Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Event-Driven

<ul>
<li>On 19 June, Eoflow announced that the U.S. Federal Appeals Court issued a decision to overturn the provisional injunction.</li>
<li>In other words, the U.S. federal court ordered the first trial's preliminary injunction banning overseas sales of Eoflow to be overturned. </li>
<li>A jury trial is set at end of November 2024. Depending on the ruling, either side may appeal and a second trial may follow or there may be a settlement.</li>
</ul>


On 19 June, Eoflow announced that the U.S. Federal Appeals Court issued a decision to overturn the provisional injunction.
In other words, the U.S. federal court ordered the first trial's preliminary injunction banning overseas sales of Eoflow to be overturned. 
A jury trial is set at end of November 2024. Depending on the ruling, either side may appeal and a second trial may follow or there may be a settlement.


Another Major Win for Eoflow [U.S. Federal Appeals Court Issues a Decision]

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>Murakami-San now owns far more in <a href="https://www.smartkarma.com/entities/mitsui-matsushima-co-ltd" target="_blank" data-smartkarma-citation="entities:13569:1" rel="noopener">Mitsui Matsushima (1518 JP)</a> than he can easily get out of other than by corporate action. Murakami-san is not a dumb guy. He knows this.</li>
<li>The unique investigative shareholder register confirms what has been long rumoured about a certain shareholder activist in <a href="https://www.smartkarma.com/entities/l-occitane-international-sa" target="_blank" data-smartkarma-citation="entities:6772:1" rel="noopener">L'Occitane (973 HK)</a>. It is also informative for what isn't present.</li>
<li>
<a href="https://www.smartkarma.com/entities/prosus-nv" target="_blank" data-smartkarma-citation="entities:28104:1" rel="noopener">Prosus (PRX NA)</a>'s discount to NAV and implied stub widened after Fabricio Bloisi's CEO appointment the previous week. But the sell-down of <a href="https://www.smartkarma.com/entities/tencent-holdings-ltd" target="_blank" data-smartkarma-citation="entities:26:1" rel="noopener">Tencent (700 HK)</a> to buy-back Prosus will continue.</li>
</ul>


Murakami-San now owns far more in Mitsui Matsushima (1518 JP) than he can easily get out of other than by corporate action. Murakami-san is not a dumb guy. He knows this.
The unique investigative shareholder register confirms what has been long rumoured about a certain shareholder activist in L'Occitane (973 HK). It is also informative for what isn't present.

Prosus (PRX NA)'s discount to NAV and implied stub widened after Fabricio Bloisi's CEO appointment the previous week. But the sell-down of Tencent (700 HK) to buy-back Prosus will continue.


Last Week in Event SPACE: Mitsui Matsushima, L'Occitane, Prosus/Tencent, EOFlow

<ul>
<li>For a company that strives to improve people's lives, investors in <a href="https://www.smartkarma.com/entities/eoflow-co-ltd" target="_blank" data-smartkarma-citation="entities:36100:1" rel="noopener">EOFlow (294090 KS)</a> shares have mostly faced a world of pain over the past year. </li>
<li>After <a href="https://www.smartkarma.com/entities/insulet-corp" target="_blank" data-smartkarma-citation="entities:5252:1" rel="noopener">Insulet Corp (PODD US)</a> filed a lawsuit on the 8th August 2023, accusing EOFlow of misappropriating trade secrets, patent infringement, and trademark dilution, shares declined ~88% by year-end.</li>
<li>Earlier this month, the courts quashed Insulet's preliminary injunction. EOFlow is up 200%. Insulet is up 3% (?).  And <a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic (MDT US)</a>, EOFlow's prior suitor, is no doubt weighing options.</li>
</ul>


For a company that strives to improve people's lives, investors in EOFlow (294090 KS) shares have mostly faced a world of pain over the past year. 
After Insulet Corp (PODD US) filed a lawsuit on the 8th August 2023, accusing EOFlow of misappropriating trade secrets, patent infringement, and trademark dilution, shares declined ~88% by year-end.
Earlier this month, the courts quashed Insulet's preliminary injunction. EOFlow is up 200%. Insulet is up 3% (?).  And Medtronic (MDT US), EOFlow's prior suitor, is no doubt weighing options.


<ul>
<li>On 8 May, Eoflow announced that the U.S. federal court has decided to suspend the effect of the first injunction decision.</li>
<li>While the effect of the second preliminary injunction decision remains intact, Eoflow has requested a review of the suspension of the effect of the second revised injunction decision as well.</li>
<li>There has been a renewed optimism on Eoflow (294090 KS)'s share price in the past week which increased by 46% from 7 May to 10 May.</li>
</ul>


On 8 May, Eoflow announced that the U.S. federal court has decided to suspend the effect of the first injunction decision.
While the effect of the second preliminary injunction decision remains intact, Eoflow has requested a review of the suspension of the effect of the second revised injunction decision as well.
There has been a renewed optimism on Eoflow (294090 KS)'s share price in the past week which increased by 46% from 7 May to 10 May.


Eoflow Announced that US Federal Court Has Decided to Suspend the Effect of 1st Injunction Decision

<ul>
<li>On 15 November, the Korea Exchange announced that Eoflow (294090 KS) will start trading again on 16 November.</li>
<li>The fact that KRX has allowed Eoflow to trade again will be viewed positively by many investors. Plus, the recent temporary ban on short selling should also positively impact Eoflow.</li>
<li>We believe a higher probability event is for Medtronic to complete a tender offer of Eoflow sometime in 2Q 2024 at about 26,000 won. </li>
</ul>


On 15 November, the Korea Exchange announced that Eoflow (294090 KS) will start trading again on 16 November.
The fact that KRX has allowed Eoflow to trade again will be viewed positively by many investors. Plus, the recent temporary ban on short selling should also positively impact Eoflow.
We believe a higher probability event is for Medtronic to complete a tender offer of Eoflow sometime in 2Q 2024 at about 26,000 won. 


Eoflow: Outlook After Trading Resumes on 16 November

South Korea

Eoflow Co.,Ltd. develops and sells medical devices. The Company produces and sells wearable disposable insulin pumps and other products. Eoflow markets its products throughout Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eoflow (294090 KS)

Another Major Win for Eoflow [U.S. Federal Appeals Court Issues a Decision]

On 19 June, Eoflow (294090 KS) announced that the U.S. Federal Appeals Court issued a decision on the 17 June to overturn the provisional injunction.

Douglas Kim

Last Week in Event SPACE: Mitsui Matsushima, L'Occitane, Prosus/Tencent, EOFlow

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

EOFlow (294090 KS): Suitably Pumped

EOFlow is free to resume global sales. Medtronic is free to reengage. I'd be buying EOFlow. Then I'd buy some more. I'd be shorting Insulet.

David Blennerhassett

Eoflow Announced that US Federal Court Has Decided to Suspend the Effect of 1st Injunction Decision

On 8 May, Eoflow announced that the U.S. federal court has decided to suspend the effect of the first injunction decision.

Douglas Kim

Eoflow: Outlook After Trading Resumes on 16 November

The Korea Exchange announced that Eoflow will start trading again on 16 November. The fact that KRX has allowed Eoflow to trade again will be...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)